Overview Safety and Tolerability of ASA404 Administered in Combination With Docetaxel in Japanese Patients With Solid Tumors Status: Completed Trial end date: 1969-12-31 Target enrollment: Participant gender: Summary This study will assess the tolerability of combination therapy with ASA404 and docetaxel in Japanese patients with advanced or recurrent solid tumors. Phase: Phase 1 Details Lead Sponsor: Novartis PharmaceuticalsTreatments: DocetaxelVadimezan